201 related articles for article (PubMed ID: 36201013)
21. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
Mutlu Sütcüoğlu B; Sütcüoğlu O
Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
[No Abstract] [Full Text] [Related]
22. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
[TBL] [Abstract][Full Text] [Related]
23. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
24. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
25. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
26. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
Ceresoli M; Verrengia A; Montori G; Busci L; Coccolini F; Ansaloni L; Frigerio L
J Gynecol Oncol; 2018 May; 29(3):e53. PubMed ID: 29533028
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
Wang JY; Gross M; Urban RR; Jorge S
Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
[TBL] [Abstract][Full Text] [Related]
28. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA; González Gil A
Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
[No Abstract] [Full Text] [Related]
29. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
32. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
Noiret B; Bakrin N; Eveno C
Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
[No Abstract] [Full Text] [Related]
33. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
34. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
35. Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Bhatt A; Bhandoria G; Kepenekian V; Bakrin N; Glehen O
Int J Cancer; 2022 Dec; 151(11):2055-2056. PubMed ID: 35857415
[No Abstract] [Full Text] [Related]
36. Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Le Saux O; Decullier E; Freyer G; Glehen O; Bakrin N
Int J Hyperthermia; 2018; 35(1):652-657. PubMed ID: 30295114
[TBL] [Abstract][Full Text] [Related]
37. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
38. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry.
Chambers LM; Yao M; Morton M; Chichura A; Costales AB; Horowitz M; Gruner MF; Rose PG; Michener CM; DeBernardo R
Int J Gynecol Cancer; 2021 Jul; 31(7):1021-1030. PubMed ID: 34006567
[TBL] [Abstract][Full Text] [Related]
39. Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Koole SN; Schouten PC; van Driel WJ; Sonke GS; Linn SC
Int J Cancer; 2022 Dec; 151(11):2057-2058. PubMed ID: 35857410
[No Abstract] [Full Text] [Related]
40. Prognostic Value of En-Block Radical Bowel Resection in Advanced Ovarian Cancer Surgery With HIPEC.
Panoskaltsis T; Papadimitriou C; Pallas N; Karamveri C; Kyziridis D; Hristakis C; Kiriakopoulos V; Kalakonas A; Vaikos D; Tzavara C; Tentes AA
Cancer Control; 2023; 30():10732748231165878. PubMed ID: 36958947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
